Efanesoctocog alfa - Bioverativ/Sanofi
Alternative Names: ALTUVIIIO; Altuviiio; Altuvoct; Antihemophilic factor (recombinant) - Bioverativ/Sanofi; BIVV-001; Factor VIII recombinant - Bioverativ/Sanofi; Fc-VWF-XTEN fusion protein-ehtl; Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion protein; rFVIIIFc-VWF-XTEN; rFVIIIFc-XTEN-vWF; XTENylated Factor VIIILatest Information Update: 22 Jul 2024
At a glance
- Originator Amunix
- Developer Amunix; Bioverativ; Sanofi; Swedish Orphan Biovitrum
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant fusion proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia A
- No development reported Von Willebrand disease
Most Recent Events
- 17 Jul 2024 Efficacy data from phase III XTEND-Kids trial in Haemophilia A released by Sanofi
- 28 Jun 2024 No recent reports of development identified for phase-I development in Von-Willebrand-disease in France (IV, Injection)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Von-Willebrand-disease in USA (IV, Injection)